MX2018013744A - Metodos para clasificar pacientes con un cancer solido. - Google Patents

Metodos para clasificar pacientes con un cancer solido.

Info

Publication number
MX2018013744A
MX2018013744A MX2018013744A MX2018013744A MX2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A MX 2018013744 A MX2018013744 A MX 2018013744A
Authority
MX
Mexico
Prior art keywords
methods
solid cancer
classifying patients
responsiveness
mean
Prior art date
Application number
MX2018013744A
Other languages
English (en)
Inventor
Galon Jérôme
Mlecnik Bernhard
Pages Franck
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2018013744A publication Critical patent/MX2018013744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

La presente invención se refiere a métodos para clasificar pacientes que padecen un cáncer sólido, en particular a métodos para el pronóstico del tiempo de supervivencia de un paciente que padece un cáncer sólido y/o a métodos para evaluar el grado de respuesta de un paciente que padece un cáncer sólido al tratamiento antitumoral. El método se basa en la cuantificación de marcadores de respuesta inmunitaria múltiple y la determinación de a qué percentil de la distribución corresponden los valores cuando se comparan con una distribución de referencia. Cálculo de la media o la mediana de los percentiles determinados de los marcadores diferentes y comparación de este valor con un valor de referencia de la media o la mediana de percentiles, cuyo resultado se correlaciona con la supervivencia y el grado de respuesta.
MX2018013744A 2016-05-09 2017-05-09 Metodos para clasificar pacientes con un cancer solido. MX2018013744A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (1)

Publication Number Publication Date
MX2018013744A true MX2018013744A (es) 2019-08-16

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013744A MX2018013744A (es) 2016-05-09 2017-05-09 Metodos para clasificar pacientes con un cancer solido.

Country Status (14)

Country Link
US (1) US20190309369A1 (es)
EP (1) EP3455631B1 (es)
JP (3) JP7281903B2 (es)
KR (1) KR102245021B1 (es)
CN (2) CN109690314B (es)
AU (1) AU2017261685B2 (es)
BR (1) BR112018072993A8 (es)
ES (1) ES2808004T3 (es)
MX (1) MX2018013744A (es)
PL (1) PL3455631T3 (es)
RU (1) RU2745730C2 (es)
SG (1) SG11201809317VA (es)
WO (1) WO2017194556A1 (es)
ZA (1) ZA201807020B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3879535A1 (en) 2017-06-13 2021-09-15 BostonGene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
EP3659110A1 (en) 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
EP3746790B1 (en) * 2018-01-31 2023-10-04 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
FR3079617B1 (fr) 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
WO2022240261A1 (ko) * 2021-05-13 2022-11-17 주식회사 센트릭스바이오 항-cd300c 단클론 항체 및 이의 암 예방 또는 치료용 바이오마커
CN110988324B (zh) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 免疫状态确定系统、方法、装置及存储介质
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
CN113174439B (zh) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
EP4330676A1 (en) * 2021-04-27 2024-03-06 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
WO2023233310A1 (en) * 2022-06-03 2023-12-07 Universita' Degli Studi Di Roma "La Sapienza" Method for determining the prognostic score in patients with metastatic renal carcinoma
CN115747331B (zh) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN117476097A (zh) * 2023-10-25 2024-01-30 中山大学附属第六医院 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ595471A (en) * 2009-04-14 2014-01-31 Nestec Sa Inflammatory bowel disease prognostics
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
JP5970560B2 (ja) * 2012-01-20 2016-08-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ細胞の密度に基づいて、固形癌に苦しむ患者の生存時間を予測するための方法
CN104541167B (zh) * 2012-06-14 2018-05-01 国家医疗保健研究所 用于定量肿瘤组织中的免疫细胞的方法及其应用
PL2872646T3 (pl) * 2012-07-12 2018-03-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby przewidywania czasu przeżycia i responsywności na leczenie pacjenta cierpiącego na nowotwór lity z sygnaturą przynajmniej 7 genów
EP3470531A1 (en) * 2012-08-06 2019-04-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for screening patients with a cancer
EP3022561B1 (en) * 2013-07-15 2019-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of survival time of a patient suffering from a solid cancer

Also Published As

Publication number Publication date
BR112018072993A2 (pt) 2019-03-06
AU2017261685B2 (en) 2023-09-07
RU2745730C2 (ru) 2021-03-31
CN109690314B (zh) 2022-08-02
EP3455631A1 (en) 2019-03-20
JP2019516979A (ja) 2019-06-20
CN109690314A (zh) 2019-04-26
JP2022027788A (ja) 2022-02-14
EP3455631B1 (en) 2020-06-24
ES2808004T3 (es) 2021-02-25
WO2017194556A1 (en) 2017-11-16
RU2018143409A3 (es) 2020-06-29
US20190309369A1 (en) 2019-10-10
ZA201807020B (en) 2020-05-27
KR102245021B1 (ko) 2021-04-26
PL3455631T3 (pl) 2021-04-06
SG11201809317VA (en) 2018-11-29
AU2017261685A1 (en) 2018-11-15
BR112018072993A8 (pt) 2022-11-08
RU2018143409A (ru) 2020-06-10
JP2024019551A (ja) 2024-02-09
KR20190016025A (ko) 2019-02-15
JP7281903B2 (ja) 2023-05-26
CN115198018A (zh) 2022-10-18

Similar Documents

Publication Publication Date Title
MX2018013744A (es) Metodos para clasificar pacientes con un cancer solido.
MX2018010362A (es) Metodos y sistemas para evaluar carga mutacional de tumores.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
TW201612855A (en) Object detecting device, object detecting method and object detecting system
MX2017007535A (es) Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
BR112017015888A2 (pt) dispositivo, adesivo de eletromiografia, e método para determinar e/ou monitorar o esforço respiratório de um indivíduo; e programa de computador
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
WO2015153948A3 (en) Microtentacle imaging in patient tumor samples
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP4265740A3 (en) Methods for predicting risk of metastasis in cutaneous melanoma
EA201692497A1 (ru) Биомаркеры ответа на ингибиторы ezh2
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
PT3289096T (pt) Processo para o prognóstico e/ou diagnóstico de uma doença à base de uma amostra de tecido adiposo
MX2020005657A (es) Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica.
MX2017009752A (es) Adn huesped como biomarcador de la enfermedad de crohn.
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
WO2017143035A3 (en) Method and therapeutic use of pign and pign-lnteractiing genes or gene products for prognosis and treatment of hematological neoplasias